WHO is the trial for?

• Patients with synovial sarcoma or Myxoid/Round Cell Liposarcom (MRCLS) that has grown or not responded to treatment, and previously received either anthracycline- or ifosfamide-based chemotherapy
• Patients who underwent pre-screening blood tests and are positive for certain proteins (HLA-A*02) as well as cancer cells tested positive for MAGE-A4 expression
• Overall health status of the patient has to be good (ECOG performance status 0 or 1)

WHAT is the key question that this trial is attempting to answer?

The trial tries to find out if the investigational drug is safe and how well it works in attacking synovial sarcoma or MRCLS cancer cells.

The investigational drug is called ADP-A2M4 and is made up of the patient's own changed T cells that are activated and increased in number in the laboratory. The process is known as gene therapy. Even though the changed T cells are taken from the patient's own blood, they are considered to be an investigational drug. Investigational means that the drug is currently being tested in study participants and has not been approved by the regulatory authorities for the treatment of patients with cancer like sarcomas.

Find out more about how gene treatment with SPEAR T cells works here (videos produced by Adaptimmune).

WHY patients might want to participate?

WHEN will the trial be open?

WHERE is the trial available?

The trial is available in several study centers in the US, Canada, France, the UK and Spain. For further information please check here:
https://clinicaltrials.gov/ct2/show/NCT04044768

Study contact:

• Deijka Aruajo, MD
  713-792-3626
  daraujo@mdanderson

STUDY DESIGN: What does the study look like?

The investigational drug is called ADP-A2M4 and is made up of the patient's own changed T cells that are activated and increased in number in the laboratory. The process is known as gene therapy. Even though the changed T cells are taken from the patient's own blood, they are considered to be an investigational drug. Investigational means that the drug is currently being tested in study participants and has not been approved by the regulatory authorities for the treatment of patients with cancer like sarcomas.

Before patients receive their changed T cells, they will have a treatment called chemotherapy that will help the body get ready to receive the investigational drug.

Patients will have:

• A leukapheresis procedure to collect T cells;
• 4 days of chemotherapy with cyclophosphamide and fludarabine;
• One-time intravenous infusion of the investigational drug;
• Follow-up visits to the study doctor.

Patients will be in the treatment phase of the study for as long as their cancer does not get worse or until they withdraw from the study. They will then be in the follow-up phase for up to 15 years after receiving the investigational drug.

HOW do I get more information?

Patient organisations supporting sarcoma and/or GIST patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving GIST and/or sarcoma patients. If there are no such organisation in your country, please email us for more information: This email address is being protected from spambots. You need JavaScript enabled to view it.

SHARE your experience

RESULTS of the study

Gene therapy is a very new approach to treat cancer. Find out more about how SPEAR T cells work here (videos produced by Adaptimmune).